SciClone Pharmaceuticals’ Danyelza Officially Launched in China for Neuroblastoma Treatment
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) has reached a significant milestone with the first prescription of...
Zai Lab’s Vyvgart Receives NMPA Approval as First-in-Class FcRn Antagonist for Myasthenia Gravis
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, has announced that the...
InnoCare Pharma and Keymed Biosciences Initiate Clinical Trial for ICP-B02 with First Subcutaneous Injection
InnoCare Pharma (HKG: 9969; SHA: 688428) and Keymed Biosciences Inc., (HKG: 2162) have announced a...
Jiangsu Hengrui Medicine Gets NMPA Approval for HRS-4357 Clinical Study in Prostate Cancer
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, has announced that...
Sichuan Biokin Pharmaceutical Gets FDA Approval for BL-B01D1 Clinical Study
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
RareStone Group’s Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China
The Center for Drug Evaluation (CDE) website in China has indicated that RareStone Group, a...
Joincare Pharmaceutical Initiates Phase III Study for Anti-IL-17A mAb in Plaque Psoriasis
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced the initiation of a...
Bio-heart’s Iberis-HTN Study Shows Promising Results in Treating Primary Hypertension
China-based Bio-heart Biological Technology Co., Ltd. (HKG: 2185) and its holding subsidiary Angiocare have announced...
Sisram Medical’s Alma Lasers Acquires PhotonMed International Ltd, Expanding Global Presence
Sisram Medical Ltd (HKG: 1696), an Israel-based company and part of the Fosun Pharmaceutical Group...
Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1
Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with...
ZSP1273 by Guangdong Zhongsheng Pharma Shows Promise in Phase III Flu Treatment Study
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced preliminary top-line...
Hansoh Pharmaceutical’s Phenylheptal Peptide Receives NMPA Approval for Anemia Treatment
The National Medical Products Administration (NMPA) has issued a marketing approval for China-based Hansoh Pharmaceutical...
Sinocelltech Group Receives NMPA Approval for Bevacizumab Biosimilar for Multiple Cancers
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received marketing approval from...
Cornerstone Robotics Secures RMB 800 Million in Funding for Surgical Robot Development
Cornerstone Robotics, a leading surgical robot developer based in Shenzhen, has reportedly raised RMB 800...
Huadong Medicine Receives NMPA Approval for DR30206 Clinical Study in Advanced Solid Tumors
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
NHSA Unveils 2023 Work Plan for National Reimbursement Drug List Update
The National Healthcare Security Administration (NHSA) has released the “Work Plan for the National Reimbursement...
Sinocelltech Group Receives NMPA Approval for COVID-19 Vaccine Bridging Phase II Study
China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Phase III Studies of Gallium Edotreotide Injection
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Jacobio Pharma Reports Promising Clinical Results for KRAS G12C Inhibitor Gecirasib in CRC
China-based Jacobio Pharma (HKG: 1167) has announced clinical results for its novel KRAS G12C inhibitor,...
Harbour BioMed’s Batoclimab for Generalized Myasthenia Gravis Accepted for NMPA Review
Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands,...